Affimed Past Earnings Performance
Past criteria checks 0/6
Affimed's earnings have been declining at an average annual rate of -37.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 2.6% per year.
Key information
-37.5%
Earnings growth rate
-19.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 2.6% |
| Return on equity | -183.3% |
| Net Margin | -761.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Affimed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 14 | -106 | 25 | 93 |
| 30 Sep 23 | 21 | -119 | 26 | 110 |
| 30 Jun 23 | 34 | -111 | 29 | 114 |
| 31 Mar 23 | 39 | -101 | 32 | 110 |
| 31 Dec 22 | 43 | -86 | 32 | 97 |
| 30 Sep 22 | 42 | -76 | 31 | 93 |
| 30 Jun 22 | 36 | -76 | 30 | 87 |
| 31 Mar 22 | 38 | -76 | 27 | 88 |
| 31 Dec 21 | 42 | -58 | 24 | 81 |
| 30 Sep 21 | 41 | -49 | 21 | 71 |
| 30 Jun 21 | 43 | -38 | 18 | 60 |
| 31 Mar 21 | 36 | -32 | 15 | 50 |
| 31 Dec 20 | 29 | -41 | 14 | 50 |
| 30 Sep 20 | 22 | -39 | 12 | 46 |
| 30 Jun 20 | 14 | -44 | 12 | 47 |
| 31 Mar 20 | 15 | -43 | 11 | 47 |
| 31 Dec 19 | 21 | -32 | 10 | 44 |
| 30 Sep 19 | 41 | -11 | 11 | 43 |
| 30 Jun 19 | 39 | -12 | 10 | 41 |
| 31 Mar 19 | 35 | -9 | 10 | 37 |
| 31 Dec 18 | 24 | -19 | 10 | 35 |
| 30 Sep 18 | 2 | -35 | 9 | 28 |
| 30 Jun 18 | 2 | -31 | 8 | 24 |
| 31 Mar 18 | 2 | -31 | 8 | 22 |
| 31 Dec 17 | 2 | -30 | 8 | 21 |
| 30 Sep 17 | 3 | -29 | 8 | 22 |
| 30 Jun 17 | 3 | -31 | 9 | 25 |
| 31 Mar 17 | 5 | -32 | 9 | 28 |
| 31 Dec 16 | 6 | -32 | 9 | 30 |
| 30 Sep 16 | 7 | -33 | 8 | 31 |
| 30 Jun 16 | 7 | -30 | 8 | 29 |
| 31 Mar 16 | 7 | -27 | 8 | 26 |
| 31 Dec 15 | 8 | -20 | 8 | 22 |
| 30 Sep 15 | 7 | -19 | 8 | 19 |
| 30 Jun 15 | 7 | -5 | 6 | 15 |
| 31 Mar 15 | 6 | 14 | 0 | 7 |
| 31 Dec 14 | 4 | 0 | 3 | 9 |
| 30 Sep 14 | 8 | 2 | 2 | 11 |
| 30 Jun 14 | 7 | -16 | 5 | 11 |
| 31 Mar 14 | 6 | -38 | 11 | 18 |
| 31 Dec 13 | 6 | -26 | 7 | 14 |
Quality Earnings: A28A is currently unprofitable.
Growing Profit Margin: A28A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A28A is unprofitable, and losses have increased over the past 5 years at a rate of 37.5% per year.
Accelerating Growth: Unable to compare A28A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A28A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: A28A has a negative Return on Equity (-183.26%), as it is currently unprofitable.